Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs
Abstract
1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Carmina, E.; Legro, R.S.; Stamets, K.; Lowell, J.; Lobo, R.A. Difference in body weight between American and Italian women with Polycystic Ovary Syndrome: Influence of the diet. Hum. Reprod. 2003, 11, 2289–2293. [Google Scholar] [CrossRef] [PubMed]
- Azziz, R.; Carmina, E.; Chen, Z.; Dunaif, A.; Laven, J.S.; Legro, R.S.; Lizneva, D.; Natterson-Horowtiz, B.; Teede, H.J.; Yildiz, B.O. Polycystic ovary syndrome. Nat. Rev. Dis. Primers 2016, 2, 16057. [Google Scholar] [CrossRef] [PubMed]
- Teede, H.J.; Misso, M.L.; Costello, M.F.; Dokras, A.; Laven, J.; Moran, L.; Piltonen, T.; Norman, R.J. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil. Steril. 2018, 110, 364–379. [Google Scholar] [CrossRef] [PubMed]
- Carmina, E.; Chu, M.C.; Longo, R.A.; Rini, G.B.; Lobo, R.A. Phenotypic Variation in Hyperandrogenic Women Influences the Findings of Abnormal Metabolic and Cardiovascular Risk Parameters. J. Clin. Endocrinol. Metab. 2005, 90, 2545–2549. [Google Scholar] [CrossRef] [PubMed]
- Essah, P.A.; Nestler, J.E.; Carmina, E. Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome. J. Endocrinol. Investig. 2008, 31, 35–41. [Google Scholar] [CrossRef] [PubMed]
- Carmina, E.; Lobo, R.A. Comparing Lean and Obese PCOS in Different PCOS Phenotypes: Evidence That the Body Weight Is More Important than the Rotterdam Phenotype in Influencing the Metabolic Status. Diagnostics 2022, 12, 2313. [Google Scholar] [CrossRef] [PubMed]
- Naderpoor, N.; Shorakae, S.; de Courten, B.; Misso, M.L.; Moran, L.J.; Teede, H. Metformin and lifestyle modification in polycystic ovary syndrome: Systematic review and meta-analysis. Hum. Reprod. Update 2015, 21, 560–574. [Google Scholar] [CrossRef] [PubMed]
- Apovian, C.M.; Aronne, L.J.; Bessesen, D.H.; McDonnell, M.E.; Murad, M.H.; Pagotto, U.; Ryan, D.H.; Still, C.D. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2015, 100, 342–362. [Google Scholar] [CrossRef]
- Näslund, E.; Barkeling, B.; King, N.; Gutniak, M.; Blundell, J.E.; Holst, J.J.; Rössner, S.; Hellström, P.M. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obes. Relat. Metab. Disord. 1999, 23, 304–311. [Google Scholar] [CrossRef]
- Mehta, A.; Marso, S.P.; Neeland, I. Liraglutide for weight management: A critical review of the evidence. J. Obes. Sci. Pract. 2017, 3, 3–14. [Google Scholar] [CrossRef]
- Ge, J.J.; Wang, D.J.; Song, W.; Shen, S.M.; Ge, W.H. The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: A meta-analysis. J. Endocrinol. Investig. 2022, 45, 261–273. [Google Scholar] [CrossRef] [PubMed]
- Jensterle, M.; Herman, R.; Janež, A. Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives. Biomedicines 2022, 10, 1989. [Google Scholar] [CrossRef] [PubMed]
- Singh, G.; Krauthamer, M.; Bjalme-Evans, M. Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management. J. Investig. Med. 2022, 70, 5–13. [Google Scholar] [CrossRef] [PubMed]
- Rubino, D.; Abrahamsson, N.; Davies, M.; Hesse, D.; Greenway, F.L.; Jensen, C.; Lingvay, I.; Mosenzon, O.; Rosenstock, J.; Rubio, M.A.; et al. STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs. Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021, 325, 1414–1425. [Google Scholar] [CrossRef] [PubMed]
- Wadden, T.A.; Bailey, T.S.; Billings, L.K.; Davies, M.; Frias, J.P.; Koroleva, A.; Lingvay, I.; O’Neil, P.M.; Rubino, D.M.; Skovgaard, D.; et al. STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA 2021, 325, 1403–1413. [Google Scholar] [CrossRef] [PubMed]
- Rubino, D.M.; Greenway, F.L.; Khalid, U.; O’Neil, P.M.; Rosenstock, J.; Sørrig, R.; Wadden, T.A.; Wizert, A.; Garvey, W.T.; The STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 2022, 327, 138–150. [Google Scholar] [CrossRef] [PubMed]
- Phillips, A.; Clements, J.N. Clinical review of subcutaneous semaglutide for obesity. J. Clin. Pharm. Ther. 2022, 47, 184–193. [Google Scholar] [CrossRef]
- Hatch, R.; Rosenfield, R.L.; Kim, M.H.; Tredway, D. Hirsutism: Implications, etiology, and management. Am. J. Obstet. Gynecol. 1981, 140, 815–830. [Google Scholar] [CrossRef]
- Carmina, E.; Azziz, R.; Bergfeld, W.; Escobar Morreale, H.F.; Futterweit, W.; Huddleston, H.; Lobo, R.A.; Olsen, E. Female pattern hair loss and androgen excess: A report from the multidisci-plinary Androgen Excess and PCOS committee. J. Clin. Endocrinol. Metab. 2019, 104, 2875–2891. [Google Scholar] [CrossRef]
- Carmina, E.; Dreno, B.; Lucky, W.A.; Agak, W.G.; Dokras, A.; Kim, J.J.; Lobo, R.A.; Tehrani, F.R.; Dumesic, D. Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. J. Endocr. Soc. 2022, 6, bvac003. [Google Scholar] [CrossRef]
- Carmina, E. Prevalence of idiopathic hirsutism. Eur. J. Endocrinol. 1998, 139, 421–423. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Carmina, E.; Longo, R.A. Increased Prevalence of Elevated DHEAS in PCOS Women with Non-Classic (B or C) Phenotypes: A Retrospective Analysis in Patients Aged 20 to 29 Years. Cells 2022, 11, 3255. [Google Scholar] [CrossRef] [PubMed]
- Carmina, E.; Stanczyk, F.; Lobo, R.A. Evaluation of hormonal status. In Jerome Strauss Robert Barbieri Antonio Gargiulo: Yen & Jaffe’s Reproductive Endocrinology, 8th ed.; Elsevier: Amsterdam, The Netherlands, 2018; Chapter 34; pp. 887–915. [Google Scholar]
- Carmina, E.; Dewailly, D.; Escobar-Morreale, H.F.; Kelestimur, F.; Moran, C.; Oberfield, S.; Witchel, S.F.; Azziz, R. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: An update with a special focus on adolescent and adult women. Hum. Reprod. Updat. 2017, 23, 580–599. [Google Scholar] [CrossRef] [PubMed]
- Dewailly, D.; Lujan, M.; Carmina, E.; Cedars, M.; Laven, J.; Norman, R.; Escobar Morreale, H. Definition and significance of polycystic ovarian morphology: A task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum. Reprod. Update 2014, 20, 334–352. [Google Scholar] [CrossRef] [PubMed]
- Pigeyre, M.; Yazdi, F.T.; Kaur, Y.; Meyre, D. Recent progress in genetics, epigenetics and meta-genomics unveils the pathophysiology of human obesity. Clin. Sci. 2016, 130, 943–986. [Google Scholar] [CrossRef] [PubMed]
- Masood, B.; Moorthy, M. Causes of obesity: A review. Clin. Med. 2023, 23, 284–291. [Google Scholar] [CrossRef]
PCOS Patients | Controls | |
---|---|---|
Age (yrs.) | 30 ± 9 | 29 ± 3 |
BMI (kg/m2) | 35.7 ± 6 ** | 23 ± 4 |
FGL index | 10 ± 2 ** | 3 ± 1 |
LH/FSH ratio | 1.7 ± 0.5 ** | 1.1 ± 0.4 |
Total testosterone (ng/dL) | 53 ± 15 ** | 22 ± 5 |
17-OH-Progesterone (ng/mL) | 1.2 ± 0.4 ** | 0.8 ± 0.2 |
Fasting glucose (mg/dL) | 98 ± 12 ** | 78 ± 9 |
Insulin (mU/mL) | 16 ± 7 ** | 9 ± 3 |
HOMA-IR | 4 ± 2 ** | 1.2 ± 0.3 |
Total Cholesterol (mg/dL) | 171 ± 22 | 168 ± 20 |
HDL Cholesterol (mg/dL) | 46 ± 8 ** | 55 ± 5 |
LDL Cholesterol (mg/dL) | 108 ± 17 | 105 ± 15 |
Triglycerides (mg/dL) | 94 ± 21 ** | 65 ± 18 |
Highly Responsive PCOS Patients (Weight Loss > 10%) | Non-Responsive PCOS Patients (Weight Loss < 5%) | |
---|---|---|
Number of patients | 9 | 6 |
BMI (kg/m2) | 32 ± 5 ** | 40 ± 5 |
Fasting glucose (mg/dL) | 94 ± 11 | 102 ± 11 |
Insulin (mU/mL) | 14.9 ± 2.9 | 17.8 ± 10 |
Homa-IR | 3.6 ± 0.5 | 4.6 ± 2 |
Basal | After 3 Months of Treatment with Semaglutide | After 6 Months of Treatment with Semaglutide | |
---|---|---|---|
BMI (kg/m2) | 34.4 ± 5.9 | 30.8 ± 5 ** | 29.4 ± 5 ** |
Body weight (kg) | 85 ±15 | 76 ± 16 ** | 73.5 ± 15 ** |
Fasting glucose (mg/dL) | 97 ± 12 | 90 ± 8 ** | 90 ± 6 ** |
Insulin (mU/mL) | 17 ± 7 | 11 ± 5 ** | 11 ± 5 ** |
HOMA-IR | 3.5 ± 2 | 2.5 ± 1 ** | 2.4 ± 0.8 ** |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Carmina, E.; Longo, R.A. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. J. Clin. Med. 2023, 12, 5921. https://doi.org/10.3390/jcm12185921
Carmina E, Longo RA. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. Journal of Clinical Medicine. 2023; 12(18):5921. https://doi.org/10.3390/jcm12185921
Chicago/Turabian StyleCarmina, Enrico, and Rosa Alba Longo. 2023. "Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs" Journal of Clinical Medicine 12, no. 18: 5921. https://doi.org/10.3390/jcm12185921
APA StyleCarmina, E., & Longo, R. A. (2023). Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. Journal of Clinical Medicine, 12(18), 5921. https://doi.org/10.3390/jcm12185921